Larynx Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LRY044 MIFTS: 60	Larynx Cancer Categories: Cancer diseases, Oral diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Larynx Cancer

MalaCards integrated aliases for Larynx Cancer:

Name: Larynx Cancer ¹² ¹⁵

Laryngeal Carcinoma ¹² ⁷⁶ ⁵³ ²⁹ ⁵⁵ ¹⁵

Laryngeal Cancer ⁵³ ³⁷ ⁵⁵

Laryngeal Benign Neoplasm ¹² ¹⁵

Carcinoma of Larynx ¹² ⁷³

Laryngeal Neoplasm ⁷⁶ ⁷³

Malignant Neoplasm of Larynx ⁷³

Laryngeal Neoplasms ⁴⁴

Neoplasm of Larynx ¹²

Cancer, Laryngeal ⁴⁰

Cancer of Larynx ¹²

Laryngeal Tumor ¹²

Larynx Neoplasm ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases Oral diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of respiratory and intrathoracic organs

Malignant neoplasm of larynx

Malignant neoplasm: Larynx, unspecified

External Ids:

Disease Ontology ¹² DOID:2596 DOID:2598 DOID:2600

ICD10 ³³ C32 C32.9

ICD9CM ³⁵ 161 161.9

MeSH ⁴⁴ D007822

NCIt ⁵⁰ C7484 C3156 C4855

SNOMED-CT ⁶⁸ 93859007

KEGG ³⁷ H00055

UMLS ⁷³ C0007107 C0023055 C0595989

Sources

Summaries for Larynx Cancer

Disease Ontology : ¹² A larynx cancer that has material basis in epithelial cells.

MalaCards based summary : Larynx Cancer, also known as laryngeal carcinoma, is related to laryngeal squamous cell carcinoma and verrucous carcinoma. An important gene associated with Larynx Cancer is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Endometrial cancer and Drug metabolism - cytochrome P450. The drugs Magnesium Sulfate and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and testes, and related phenotypes are Reduced mammosphere formation and digestive/alimentary

Wikipedia : ⁷⁶ Laryngeal cancer, also known as cancer of the larynx or laryngeal carcinoma, are mostly squamous cell... more...

Sources

Related Diseases for Larynx Cancer

Diseases in the Larynx Cancer family:

Larynx Carcinoma in Situ

Diseases related to Larynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)

#	Related Disease	Score	Top Affiliating Genes
1	laryngeal squamous cell carcinoma	31.3	CCND1 CDKN2A EGFR GSTM3 GSTT1 MIR21
2	verrucous carcinoma	30.2	CCND1 CDKN2A TP53
3	in situ carcinoma	29.9	CDKN2A EGFR TP53
4	asbestosis	29.8	GSTM1 GSTP1 GSTT1
5	inverted papilloma	29.7	CCND1 CDKN2A TP53
6	small cell carcinoma	29.7	CDKN2A EGFR TP53
7	malignant peritoneal mesothelioma	29.7	CDKN2A EGFR
8	oropharynx cancer	29.7	CCND1 CDKN2A EGFR TP53
9	basaloid squamous cell carcinoma	29.6	CDKN2A EGFR TP53
10	adenocarcinoma	29.4	CCND1 CDKN2A EGFR TP53
11	lynch syndrome	29.3	CCND1 CDKN2A EGFR GSTM1 TP53
12	squamous cell carcinoma	29.2	CCND1 CD44 CDKN2A EGFR GSTP1 MMP2
13	thyroid cancer	29.1	CCND1 EGFR GSTT1 TERT TP53
14	pancreatic cancer	29.0	CCND1 CD44 CDKN2A DLEU2 EGFR MIR21
15	nasopharyngeal carcinoma	28.8	CCND1 CDKN2A EGFR GSTM1 MMP2 NME1
16	ovarian cancer	28.6	CCND1 CD44 EGFR GSTP1 MIR21 MMP2
17	cervical cancer	28.4	CCND1 CD44 CDKN2A FHIT GSTM1 GSTP1
18	esophageal cancer	28.2	CCND1 CD44 CDKN2A EGFR FHIT GSTM1
19	lung cancer	28.1	CCND1 CD44 CDKN2A EGFR FHIT GSTM1
20	breast cancer	28.0	CCND1 CD44 CTSD EGFR FHIT GSTP1
21	laryngeal cancer, childhood	12.1
22	supraglottic laryngeal cancer	11.5
23	laryngeal neuroendocrine tumor	11.1
24	laryngeal mucoepidermoid carcinoma	11.1
25	laryngeal adenoid cystic carcinoma	11.1
26	laryngeal small cell carcinoma	11.1
27	larynx sarcoma	11.0
28	colorectal cancer, childhood	10.3	GSTM1 NAT2
29	hearing loss, noise-induced	10.3	GSTM1 GSTT1
30	sister chromatid exchange, frequency of	10.3	GSTM1 GSTT1
31	drug-induced hepatitis	10.3	GSTM1 GSTT1 NAT2
32	diffuse gastric cancer	10.2	GSTM1 GSTP1 GSTT1
33	xeroderma pigmentosum, complementation group d	10.2	GSTM1 GSTP1 GSTT1
34	breast papillomatosis	10.2	CCND1 CDKN2A
35	gastric adenosquamous carcinoma	10.2	CD44 CDKN2A TP53
36	tonsil squamous cell carcinoma	10.2	CCND1 CDKN2A
37	bladder squamous cell carcinoma	10.2	CDKN2A TP53
38	keratinizing squamous cell carcinoma	10.2	CDKN2A TP53
39	hypoxia	10.2
40	oral leukoplakia	10.2	CDKN2A GSTM1 GSTT1 TP53
41	male reproductive system disease	10.2	CCND1 GSTP1 TP53
42	spitz nevus	10.2	CDKN2A TP53
43	tongue disease	10.2	CDKN2A MMP2 TP53
44	cardia cancer	10.2	GSTM1 GSTP1 GSTT1 TP53
45	skin carcinoma in situ	10.2	CCND1 CDKN2A
46	acute lymphocytic leukemia	10.2	CDKN2A GSTM1 GSTT1 TP53
47	actinic keratosis	10.1	CDKN2A MMP2 TP53
48	nasopharyngeal disease	10.1	CCND1 CDKN2A TP53
49	retinal cancer	10.1	CCND1 CDKN2A TP53
50	ocular cancer	10.1	CCND1 CDKN2A TP53

Comorbidity relations with Larynx Cancer via Phenotypic Disease Network (PDN):

Bronchitis	Deficiency Anemia
Pharynx Cancer	Protein-Energy Malnutrition
Respiratory Failure	Supraglottis Cancer
Swallowing Disorders

Graphical network of the top 20 diseases related to Larynx Cancer:

Sources

Symptoms & Phenotypes for Larynx Cancer

GenomeRNAi Phenotypes related to Larynx Cancer according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.17	CCND1 CD44 EGFR GSTM1 GSTM3 MMP2

MGI Mouse Phenotypes related to Larynx Cancer:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	10.02	CCND1 CD44 CDKN2A CTSD EGFR ENG
2	hematopoietic system	MP:0005397	10.02	CCND1 CD44 CDKN2A CTSD EGFR ENG
3	mortality/aging	MP:0010768	9.93	CCND1 CD44 CDKN2A CTSD EGFR ENG
4	integument	MP:0010771	9.91	CCND1 CD44 CDKN2A CTSD EGFR ENG
5	neoplasm	MP:0002006	9.61	CCND1 CD44 CDKN2A EGFR FHIT MMP2
6	respiratory system	MP:0005388	9.23	CCND1 CD44 CDKN2A EGFR ENG MMP2

Sources

Drugs & Therapeutics for Larynx Cancer

Drugs for Larynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Magnesium Sulfate

Approved, Investigational, Vet_approved

Phase 4

7487-88-9

24083

Dopamine

Approved

Phase 4,Phase 2

51-61-6, 62-31-7

681

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Nicotine

Approved

Phase 4,Not Applicable

54-11-5

942 89594

Analgesics

Phase 4,Phase 1,Phase 2,Not Applicable

Anesthetics

Phase 4,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Central Nervous System Depressants

Phase 4,Not Applicable

Liver Extracts

Phase 4,Phase 2,Not Applicable

Cytochrome P-450 Enzyme Inhibitors

Phase 4,Phase 2

Neurotransmitter Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Pharmaceutical Solutions

Phase 4

calcium channel blockers

Phase 4

Tocolytic Agents

Phase 4

Calcium, Dietary

Phase 4

Anticonvulsants

Phase 4

Anti-Arrhythmia Agents

Phase 4

Antidepressive Agents

Phase 4,Phase 2

Antidepressive Agents, Second-Generation

Phase 4,Phase 2

Dopamine Uptake Inhibitors

Phase 4,Phase 2

Neurotransmitter Uptake Inhibitors

Phase 4,Phase 2

Psychotropic Drugs

Phase 4,Phase 2

Dopamine Agents

Phase 4,Phase 2

Cytochrome P-450 CYP2D6 Inhibitors

Phase 4,Phase 2

Nicotinic Agonists

Phase 4,Not Applicable

Cholinergic Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Autonomic Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Central Nervous System Stimulants

Phase 4,Not Applicable

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1

51-21-8

3385

Docetaxel

Approved, Investigational

Phase 3,Phase 2,Phase 1

114977-28-5

148124

Ethanol

Approved

Phase 3

64-17-5

702

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Hydroxyurea

Approved

Phase 3,Phase 2

127-07-1

3657

Cobalt

Approved, Experimental

Phase 3

7440-48-4

104729

Nicotinamide

Approved, Investigational

Phase 3

98-92-0

936

Cefazolin

Approved

Phase 3

25953-19-9

656510 33255

Pilocarpine

Approved, Investigational

Phase 2, Phase 3

54-71-7, 92-13-7

5910

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 1

59-30-3

6037

Niacin

Approved, Investigational, Nutraceutical

Phase 3

59-67-6

938

Antimetabolites

Phase 3,Phase 2,Phase 1,Not Applicable

Immunologic Factors

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Infective Agents

Phase 3,Phase 1,Phase 2,Not Applicable

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2,Phase 1

Vasodilator Agents

Phase 3

Vitamin B9

Phase 3,Phase 1

Vitamins

Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 150)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Magnesium Sulphate Infusion on Lung Mechanics and Oxygenation in COPD Patients Undergoing Total Laryngeal	Completed	NCT03461328	Phase 4	Magnesium Sulphate
2	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
3	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
4	the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy	Unknown status	NCT00497588	Phase 3
5	Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx	Completed	NCT00002496	Phase 3	chemotherapy;cisplatin;fluorouracil
6	Randomized Trial of ARCON in Larynx Cancer	Completed	NCT00147732	Phase 3
7	Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma	Completed	NCT00169182	Phase 3	DOCETAXEL
8	Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx	Completed	NCT00002839	Phase 3	cisplatin;fluorouracil
9	Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients	Completed	NCT00467948	Phase 3	cefazolin
10	Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population	Completed	NCT00359645	Phase 3
11	Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC	Completed	NCT00162708	Phase 2, Phase 3	CDDP, 5 Fu
12	Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC	Completed	NCT00158652	Phase 3	5FU, Paraplatin
13	Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)	Completed	NCT00117572	Phase 3	docetaxel;cisplatin;hydroxyurea;fluorouracil
14	Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer	Completed	NCT00656513	Phase 2, Phase 3	Pilocarpine
15	Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer	Completed	NCT00008398	Phase 3
16	Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection	Recruiting	NCT02918955	Phase 3	Chemotherapy (Cisplatin)
17	Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence	Withdrawn	NCT01142414	Phase 3	cisplatin;fluorouracil
18	Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer	Unknown status	NCT01073683	Phase 2	Taxotere (Docetaxel), Cisplatin, 5FU
19	TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer	Unknown status	NCT00765011	Phase 2	TPF, radiotherapy and cetuximab
20	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx	Unknown status	NCT00004094	Phase 2	carboplatin;fluorouracil;hydroxyurea;paclitaxel
21	Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer	Unknown status	NCT00003251	Phase 1, Phase 2	amifostine trihydrate;cisplatin;paclitaxel
22	Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck	Unknown status	NCT00003182	Phase 1, Phase 2	cisplatin;gemcitabine hydrochloride
23	Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer	Unknown status	NCT00003777	Phase 2	amifostine trihydrate;cisplatin;fluorouracil
24	Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer	Unknown status	NCT00003327	Phase 2	paclitaxel
25	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases	Unknown status	NCT00637637	Phase 2	indinavir sulfate;ritonavir
26	Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer	Completed	NCT00827164	Phase 2
27	Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer	Completed	NCT00004256	Phase 2
28	Clinical Feasibility of New Tracheoesophageal Puncture Set	Completed	NCT01045057	Phase 1, Phase 2
29	Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer	Completed	NCT02048020	Phase 2	paclitaxel;carboplatin
30	Endoscopic Surgery or Radiation Therapy in Treating Patients With Stage 0, Stage I, or Stage II Laryngeal Cancer of the Glottis	Completed	NCT00334997	Phase 2
31	Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx	Completed	NCT00243113	Phase 2	docetaxel
32	Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx	Completed	NCT00498953	Phase 1, Phase 2	carboplatin;cisplatin;docetaxel;fluorouracil;lapatinib ditosylate
33	Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation	Completed	NCT00169247	Phase 2	cetuximab;Cisplatin
34	Efficacy of Hyperbaric Oxygen Therapy in Laryngectomy Patients	Completed	NCT00026975	Phase 2
35	Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis	Completed	NCT00743262	Phase 1, Phase 2
36	A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab	Completed	NCT01435252	Phase 2	Cetuximab
37	Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer	Completed	NCT00014118	Phase 2	carboplatin;paclitaxel
38	Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer	Completed	NCT00970502	Phase 1, Phase 2	erlotinib + celecoxib
39	Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer	Completed	NCT00462735	Phase 2	Cetuximab;Hydroxyurea;Fluorouracil
40	Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer	Completed	NCT00833261	Phase 2	cetuximab;cisplatin
41	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.	Completed	NCT01469429	Phase 1, Phase 2	chemoprevention;chemoprevention
42	Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer	Completed	NCT00002964	Phase 2	porfimer sodium
43	Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer	Completed	NCT00002951	Phase 2	fluorouracil;hydroxyurea
44	Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract	Completed	NCT00524017	Phase 2
45	Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia	Completed	NCT00052611	Phase 2	Celecoxib
46	Bupropion in Helping Adults Stop Smoking	Completed	NCT00534001	Phase 2	bupropion hydrochloride
47	Zinc Supplements in Lowering Cadmium Levels in Smokers	Completed	NCT00376987	Phase 2
48	Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer	Recruiting	NCT02849314	Phase 1, Phase 2
49	Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer	Recruiting	NCT03759431	Phase 2
50	A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma	Recruiting	NCT02759575	Phase 1, Phase 2	Pembrolizumab;Cisplatin

Search NIH Clinical Center for Larynx Cancer

Cochrane evidence based reviews: laryngeal neoplasms

Sources

Genetic Tests for Larynx Cancer

Genetic tests related to Larynx Cancer:

#	Genetic test	Affiliating Genes
1	Laryngeal Carcinoma ²⁹

Sources

Anatomical Context for Larynx Cancer

MalaCards organs/tissues related to Larynx Cancer:

⁴¹

Skin, Lymph Node, Testes, Lung, Thyroid, Endothelial, Breast

Sources

Publications for Larynx Cancer

Articles related to Larynx Cancer:

(show top 50) (show all 1225)

#	Title	Authors	Year
1	Quality of life in patients with larynx cancer in Latin America: Comparison between laryngectomy and organ preservation protocols. ( 29554402 )	Sanabria A....Alvarez A.	2018
2	Epidemiological features of cancers of the oral cavity, oropharynx, hypopharynx and larynx cancer in RAcunion Island. ( 29673737 )		2018
3	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. ( 29598944 )		2018
4	Laryngeal Tuberculosis Mimicking Laryngeal Carcinoma on <sup>18</sup>F-FDG PET/CT Imaging. ( 29889030 )		2018
5	Comparative p16IKN4A Expression in Laryngeal Carcinoma and Cervical Cancer Precursors: A Real-time Grid-based Immunocytochemistry Analysis. ( 30275203 )	Tsiambas E...Ragos V	2018
6	Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients. ( 28685830 )	Day AT...Gourin CG	2018
7	Impact of HPV Status on the Prognostic Potential of the AJCC Staging System for Larynx Cancer. ( 29611770 )	Davidson SM...Witek ME	2018
8	Does Socioeconomic Status Affect Stage at Presentation for Larynx Cancer in Canada's Universal Health Care System? ( 30200820 )	Khalil D...Johnson-Obaseki S	2018
9	Decision making in advanced larynx cancer: An evidenced based review. ( 30409301 )	Eskander A...Dziegielewski PT	2018
10	From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer. ( 30409302 )	Spector ME...Birkeland AC	2018
11	Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies. ( 30409316 )	Bonomi MR...Blakaj D	2018
12	Association of Hospital Volume With Laryngectomy Outcomes in Patients With Larynx Cancer. ( 30476965 )	Gourin CG...Austin JM	2018
13	Lemierre Syndrome as a Complication of Laryngeal Carcinoma. ( 29849275 )	Colbert C...Bull L	2018
14	Neutrophil-Lymphocyte Ratio as a Prognostic Factor in Laryngeal Carcinoma. ( 29977836 )	Y?lmaz B...Top?u ?	2018
15	MicroRNA-138 inhibits proliferation and induces apoptosis of laryngeal carcinoma via targeting MAPK6. ( 30229830 )	Zhou YH...Ma M	2018
16	Prevention of anastomotic leak using an advanced pectoral flap in total pharyngolaryngectomy and free jejunal reconstruction for hypopharyngeal or laryngeal carcinoma. ( 30261803 )	Kondo T...Ogawa Y	2018
17	Human papillomavirus infection in patients with laryngeal carcinoma. ( 30342481 )	Onerci Celebi O...Guler Tezel G	2018
18	Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration. ( 30361911 )	Yu D...Xu C	2018
19	Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro. ( 30464533 )	Jiang T...Fan J	2018
20	Identification of Integrin β1 as a Novel PAG1-Interacting Protein Involved in the Inherent Radioresistance of Human Laryngeal Carcinoma. ( 30519312 )	Dong X...Shen L	2018
21	Survival analysis of distant metastasis of laryngeal carcinoma: analysis based on SEER database. ( 30542764 )	Pan Y...Zhuang W	2018
22	Knockdown of DGCR5 enhances the radiosensitivity of human laryngeal carcinoma cells via inducing miR-195. ( 30549038 )	Tang T...Zeng F	2018
23	EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma. ( 28795320 )	Lian R...Yu W	2018
24	Does CT help in predicting preepiglottic space invasion in laryngeal carcinoma? ( 28807527 )	Bozkurt G...Co?kun BU	2018
25	Prognostic significance of soft tissue deposits in laryngeal carcinoma. ( 28823696 )	Ozmen OA...Basut OI	2018
26	The incidence of thyroid cartilage invasion in early-stage laryngeal carcinoma: Our experience on sixty-two patients. ( 28994198 )	Yener HM...Karaman E	2018
27	Transoral laser surgery for laryngeal carcinoma: has Steiner achieved a genuine paradigm shift in oncological surgery? ( 29046085 )	Harris AT...Taylor SM	2018
28	Altered O-glycosylation is associated with inherent radioresistance and malignancy of human laryngeal carcinoma. ( 29179977 )	Dong X...Shen L	2018
29	Beclin1 enhances cisplatin-induced apoptosis via Bcl-2-modulated autophagy in laryngeal carcinoma cells Hep-2. ( 29322787 )	Yang M...Li SS	2018
30	Feasibility of Salvage Selective Neck Dissection after Primary Irradiation of Pharyngeal and Laryngeal Carcinoma. ( 29428959 )	Mat Lazim N...Tan IB	2018
31	NBS1 rs2735383 polymorphism is associated with an increased risk of laryngeal carcinoma. ( 29433451 )	Hu X...Nong Q	2018
32	Fasudil inhibits proliferation and migration of Hep-2 laryngeal carcinoma cells. ( 29503530 )	Zhang X...Wu N	2018
33	Variation in prognosis of early laryngeal carcinoma after different types of cordectomy with transoral laser microsurgery. ( 29504443 )	Ding S...Zhang Y	2018
34	TIMP-3 increases the chemosensitivity of laryngeal carcinoma to cisplatin via facilitating mitochondria-dependent apoptosis. ( 29523219 )	Shen X...Wang J	2018
35	The value of whole-body contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of patients with laryngeal carcinoma. ( 29533345 )	Tatar G...Yigit O	2018
36	MiR-632 promotes laryngeal carcinoma cell proliferation, migration and invasion through negative regulation of GSK3β. ( 29562960 )	Zhou ZX...Tan TZ	2018
37	Laryngeal carcinoma in a father and son. Possible familial risk? ( 29619497 )	Al-Otaibi SS...Khoja HA	2018
38	Long non-coding RNA Dleu2 affects proliferation, migration and invasion ability of laryngeal carcinoma cells through triggering miR-16-1 pathway. ( 29687850 )	Xie ZZ...Tan GL	2018
39	High PINCH1 Expression in Human Laryngeal Carcinoma Associates with Poor Prognosis. ( 29755929 )	Tsinias G...Bravou V	2018
40	Solitary femoral metastasis in a locoregionally controlled laryngeal carcinoma. ( 29761605 )	Wong WK...Vokes D	2018
41	Alterations in oxidative stress markers in laryngeal carcinoma patients. ( 29778552 )	Bozan N...?ankaya H	2018
42	Oncological and functional outcomes of transoral laser surgery for laryngeal carcinoma. ( 29869708 )	Pedregal-Mallo D...Rodrigo JP	2018
43	Combined treatment with acetazolamide and cisplatin enhances chemosensitivity in laryngeal carcinoma Hep-2 cells. ( 29928333 )	Gao H...Jin H	2018
44	Nuclear nonmetastatic protein 23-H1 expression and epithelial-mesenchymal transition in laryngeal carcinoma: A pilot investigation. ( 29953715 )	Marioni G...Blandamura S	2018
45	Long non-coding RNA AFAP1-AS1/miR-320a/RBPJ axis regulates laryngeal carcinoma cell stemness and chemoresistance. ( 29971915 )	Yuan Z...Jia S	2018
46	Effects of Different Treatment Strategies and Tumor Stage on Survival of Patients with Advanced Laryngeal Carcinoma: A 15-Year Cohort Study. ( 29973955 )	Daneshi N...Dianatinasab M	2018
47	Downregulation of miRNA-26b inhibits cancer proliferation of laryngeal carcinoma through autophagy by targeting ULK2 and inactivation of the PTEN/AKT pathway. ( 28713931 )	Wang S....Li C.	2017
48	Salvage Surgery after Radiation Failure in T1/T2 Larynx Cancer: Outcomes following Total versus Conservation Surgery. ( 29292665 )	Cheraghlou S....Judson B.L.	2017
49	MiR-503 enhances the radiosensitivity of laryngeal carcinoma cells via the inhibition of WEE1. ( 29019284 )	Ma H....Guo X.	2017
50	Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells. ( 28123594 )	Grabarska A....Stepulak A.	2017

Sources

Genes for Larynx Cancer

Genes related to Larynx Cancer (1 elite genes):

(show all 22)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MIR21	MicroRNA 21	RNA Gene	350	Causal ⁴⁷	19546886
2	DLEU2	Deleted In Lymphocytic Leukemia 2	RNA Gene	156.34	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵ ¹⁵
3	FAM3D-AS1	FAM3D Antisense RNA 1	RNA Gene	150	Experimental evidence: Regulation ³⁹	25904139
4	GSTT1	Glutathione S-Transferase Theta 1	Protein Coding	39.31	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8561822 11097350 9456238 (more) 12359356 10067818
5	NME1	NME/NM23 Nucleoside Diphosphate Kinase 1	Protein Coding	33.11	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	12768677 12014221 11265374 (more) 12815897 9616278 9642340 18476632 11080791 11387948 12764847 8635091 11189167
6	GSTM1	Glutathione S-Transferase Mu 1	Protein Coding	32.52	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	15127559 11097350 9456238 (more) 12359356 12748560 10067818 14594555 11477586
7	GSTM3	Glutathione S-Transferase Mu 3	Protein Coding	31.69	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10067818 12359356 10407823
8	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	31.49	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
9	TP53	Tumor Protein P53	Protein Coding	30.75	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	11699821 12600081 8386140 (more) 12815897 11205233 12881872 7654413 18800676 9687893 12768762 9193221 15835821 11189420 18330257 8762527 7781800 10073037 8780536 11265384 17207318 10875157 9874454 7788934 10499619 9097709 17352251 20108544 9563667 9197477 19160427 18476631 11829192 11400228 12768677 9197495 18559058 18519232 16075975 15067348 11200824 9583028 10323025 15039212 12536563 10852523 16891205 16809096 15831046 12175687 10810258 10337529 8616872 9445184 15467627 12656410 12541678 9267820 19072995 18509272 14551784 10953333 10419041 19724860 11520092 12761983
10	MMP2	Matrix Metallopeptidase 2	Protein Coding	29.03	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	17888194 18062285 18431027 (more) 10320094 17649730 11843925
11	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	29.01	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
12	CCND1	Cyclin D1	Protein Coding	28.43	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	15354413 17139501 14551784 (more) 16881553 18329328 11189154 9738577 9816104 15467627 19160427 12669430 18268491 16270530 9545767 15509364 8616872 19724860 12649172
13	CTSD	Cathepsin D	Protein Coding	28.24	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	10850757 9135974 8962695 (more) 8608976 11080791 10652611 11299783 8443785 12528259 11012985
14	NAT2	N-Acetyltransferase 2	Protein Coding	27.69	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12015038 10208649
15	TERT	Telomerase Reverse Transcriptase	Protein Coding	27.6	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	17592663 19159530
16	GSTP1	Glutathione S-Transferase Pi 1	Protein Coding	26.69	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10067818 12359356
17	FHIT	Fragile Histidine Triad	Protein Coding	26.64	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	11776620 18476633 18357366
18	HSP90AB1	Heat Shock Protein 90 Alpha Family Class B Member 1	Protein Coding	26.54	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	10920983 11717891
19	EGFR	Epidermal Growth Factor Receptor	Protein Coding	26.25	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	19427146 11721445 12541404 (more) 9639720 19148533 17190429 15338866 1516034 18172732 18329328 10932015 9271009 8291440 20052590 20512084 9197492 19789511 9197495 14666705 8616872
20	ENG	Endoglin	Protein Coding	26.16	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	18383901 18330257
21	SERPINB5	Serpin Family B Member 5	Protein Coding	26.09	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵	18439947 15842640 17214364 (more) 18236066
22	PTEN	Phosphatase And Tensin Homolog	Protein Coding	26.03	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
22	PTEN::MIR21 ⁴⁷	MIR21 Macro RNA (hsa-miR-21) targets PTEN

Sources

Variations for Larynx Cancer

Cosmic variations for Larynx Cancer:

⁹ (show top 50) (show all 319)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM6927812	ZFHX3	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.4946C>T	p.S1649F	16:72797736-72797736	14
2	COSM45571	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.593A>G	p.E198G	17:7674938-7674938	14
3	COSM10662	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	14
4	COSM10995	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.580C>T	p.L194F	17:7674951-7674951	14
5	COSM11066	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.578A>T	p.H193L	17:7674953-7674953	14
6	COSM10714	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.473G>T	p.R158L	17:7675139-7675139	14
7	COSM43690	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.592G>A	p.E198K	17:7674939-7674939	14
8	COSM10905	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.451C>T	p.P151S	17:7675161-7675161	14
9	COSM10779	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.818G>T	p.R273L	17:7673802-7673802	14
10	COSM10888	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.378C>A	p.Y126*	17:7675234-7675234	14
11	COSM10808	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.488A>G	p.Y163C	17:7675124-7675124	14
12	COSM6549	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.743G>T	p.R248L	17:7674220-7674220	14
13	COSM12559	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.673-2A>T	p.?	17:7674292-7674292	14
14	COSM43846	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.487T>C	p.Y163H	17:7675125-7675125	14
15	COSM10893	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.824G>A	p.C275Y	17:7673796-7673796	14
16	COSM10659	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.817C>T	p.R273C	17:7673803-7673803	14
17	COSM44475	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.871A>T	p.K291*	17:7673749-7673749	14
18	COSM10813	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.394A>G	p.K132E	17:7675218-7675218	14
19	COSM11462	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.388C>G	p.L130V	17:7675224-7675224	14
20	COSM44219	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.405C>G	p.C135W	17:7675207-7675207	14
21	COSM6906	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.672+1G>A	p.?	17:7674858-7674858	14
22	COSM44067	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.721T>A	p.S241T	17:7674242-7674242	14
23	COSM11658	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.955A>T	p.K319*	17:7673573-7673573	14
24	COSM44071	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.955A>G	p.K319E	17:7673573-7673573	14
25	COSM11305	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.809T>C	p.F270S	17:7673811-7673811	14
26	COSM44352	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.850A>C	p.T284P	17:7673770-7673770	14
27	COSM43583	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.425C>T	p.P142L	17:7675187-7675187	14
28	COSM10889	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.536A>G	p.H179R	17:7675076-7675076	14
29	COSM10758	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.659A>G	p.Y220C	17:7674872-7674872	14
30	COSM10660	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.818G>A	p.R273H	17:7673802-7673802	14
31	COSM10777	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.715A>G	p.N239D	17:7674248-7674248	14
32	COSM10742	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.578A>G	p.H193R	17:7674953-7674953	14
33	COSM44456	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.668C>A	p.P223H	17:7674863-7674863	14
34	COSM11166	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.406C>T	p.Q136*	17:7675206-7675206	14
35	COSM10810	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.725G>T	p.C242F	17:7674238-7674238	14
36	COSM43949	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.401T>G	p.F134C	17:7675211-7675211	14
37	COSM43935	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.577C>A	p.H193N	17:7674954-7674954	14
38	COSM10645	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.527G>T	p.C176F	17:7675085-7675085	14
39	COSM44103	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.737T>A	p.M246K	17:7674226-7674226	14
40	COSM10654	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.637C>T	p.R213*	17:7674894-7674894	14
41	COSM44143	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.919+1G>A	p.?	17:7673700-7673700	14
42	COSM10648	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.524G>A	p.R175H	17:7675088-7675088	14
43	COSM44278	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.791T>C	p.L264P	17:7673829-7673829	14
44	COSM43826	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.706T>A	p.Y236N	17:7674257-7674257	14
45	COSM98254	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.782+1G>A	p.?	17:7674180-7674180	14
46	COSM11374	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.752T>A	p.I251N	17:7674211-7674211	14
47	COSM44678	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.415A>T	p.K139*	17:7675197-7675197	14
48	COSM43947	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.614A>G	p.Y205C	17:7674917-7674917	14
49	COSM45544	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.947C>T	p.P316L	17:7673581-7673581	14
50	COSM11081	TP53	upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma	c.733G>T	p.G245C	17:7674230-7674230	14

Sources

Expression for Larynx Cancer

Search GEO for disease gene expression data for Larynx Cancer.

Sources

Pathways for Larynx Cancer

Pathways related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 32)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.76	CCND1 CDKN2A EGFR GSTP1 HSP90AB1 TP53
2	Drug metabolism - cytochrome P450 ³⁷ Show member pathways Aflatoxin B1 metabolism ¹ Artemisinin and Derivatives Pathway, Pharmacokinetics ⁶¹ Arylamine metabolism ¹ Benzo[a]pyrene metabolism ²² Benzodiazepine Pathway, Pharmacokinetics ⁶¹ Celecoxib Pathway, Pharmacokinetics ⁶¹ Chemical carcinogenesis ³⁷ Drug metabolism - other enzymes ³⁷ Fluvoxamine Pathway, Pharmacokinetics ⁶¹ Haloperidol Pathway, Pharmacokinetics ⁶¹ Ifosfamide Pathway, Pharmacokinetics ⁶¹ Metabolism of xenobiotics by cytochrome P450 ³⁷ Naproxen Pathway, Pharmacokinetics ⁶¹ Oxycodone Pathway, Pharmacokinetics ⁶¹ Retinol metabolism ²² Retinol metabolism ³⁷ Voriconazole Pathway, Pharmacokinetics ⁶¹	12.7	GSTM1 GSTM3 GSTP1 GSTT1 NAT2 NME1
3	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.63	CCND1 CDKN2A EGFR FHIT MMP2 TP53
4	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.58	CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
5	DNA Damage ⁴	12.42	CCND1 CDKN2A GSTP1 TP53
6	MicroRNAs in cancer ³⁷	12.39	CCND1 CD44 CDKN2A EGFR MIR21 TP53
7	Human T-cell leukemia virus 1 infection ³⁷	12.34	CCND1 CDKN2A TERT TP53
8	Glutathione metabolism ²² ¹ ³⁷ Show member pathways 4-hydroxy-2-nonenal detoxification ¹ gamma-glutamyl cycle ¹ Glutathione conjugation ⁶⁶ glutathione redox reactions I ¹ Glutathione synthesis and recycling ⁶⁶ glutathione-mediated detoxification ¹	12.21	GSTM1 GSTM3 GSTP1 GSTT1
9	Proteoglycans in cancer ³⁷	12.18	CCND1 CD44 EGFR MIR21 MMP2 TP53
10	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.12	CCND1 EGFR HSP90AB1 TP53
11	Colorectal Cancer Metastasis ⁶⁴	12.09	CCND1 EGFR MMP2 TP53
12	Pathways in cancer ³⁷	12.08	CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
13	AKT Signaling Pathway ⁶⁷	12.05	CCND1 EGFR HSP90AB1 TP53
14	NRF2 pathway ¹	12.02	GSTM1 GSTM3 GSTP1 HSP90AB1
15	Direct p53 effectors ¹	11.97	CTSD EGFR MMP2 TP53
16	Senescence and Autophagy in Cancer ¹	11.86	CD44 CDKN2A TP53
17	Glioblastoma Multiforme ⁶⁴	11.84	CCND1 CDKN2A EGFR TP53
18	Small cell lung cancer ³⁷	11.79	CCND1 FHIT TP53
19	Validated targets of C-MYC transcriptional activation ¹	11.71	NME1 TERT TP53
20	Acetaminophen Pathway (therapeutic doses), Pharmacokinetics ⁶¹ Show member pathways 2-Naphthylamine and 2-Nitronaphtalene metabolism ²² Acetaminophen metabolism ²² Acetaminophen Pathway (toxic doses), Pharmacokinetics ⁶¹	11.7	GSTM1 GSTP1 GSTT1
21	Regulation of Wnt-mediated beta catenin signaling and target gene transcription ¹	11.69	CCND1 MMP2 TERT
22	Fluid shear stress and atherosclerosis ³⁷	11.64	GSTM1 GSTM3 GSTP1 GSTT1 HSP90AB1 MMP2
23	Bladder cancer ³⁷ ¹	11.63	CCND1 CDKN2A EGFR MMP2 TP53
24	Regulation of Telomerase ¹	11.61	CCND1 EGFR TERT
25	Cell adhesion_ECM remodeling ²²	11.56	CD44 EGFR MMP2
26	Platinum drug resistance ³⁷	11.5	CDKN2A GSTM1 GSTM3 GSTP1 GSTT1 TP53
27	Hepatitis C and Hepatocellular Carcinoma ¹	11.47	CCND1 CD44 TP53
28	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.43	CCND1 CDKN2A EGFR MMP2 TP53
29	Busulfan Pathway, Pharmacodynamics ⁶¹ Show member pathways Catalytic cycle of mammalian Flavin-containing MonoOxygenases (FMOs) ¹ FMO oxidises nucleophiles ⁶⁶	11.39	GSTM1 GSTP1 NAT2
30	Platinum Pathway, Pharmacokinetics/Pharmacodynamics ⁶¹	11.15	GSTM1 GSTP1 GSTT1
31	Naphthalene metabolism ²²	11.01	GSTM1 GSTP1 GSTT1
32	Etoposide Pathway, Pharmacokinetics/Pharmacodynamics ⁶¹	10.82	GSTP1 GSTT1

Sources

GO Terms for Larynx Cancer

Cellular components related to Larynx Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:0005737	9.8	CCND1 CDKN2A EGFR FHIT GSTM1 GSTM3
2	cytosol	GO:0005829	9.44	CCND1 CD44 CDKN2A FHIT GSTM1 GSTM3

Biological processes related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 19)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.87	ENG MIR21 NME1 TERT
2	positive regulation of protein phosphorylation	GO:0001934	9.8	CCND1 EGFR ENG MIR21
3	negative regulation of apoptotic process	GO:0043066	9.8	CD44 EGFR GSTP1 HSP90AB1 MIR21 TERT
4	positive regulation of protein kinase B signaling	GO:0051897	9.78	EGFR ENG HSP90AB1 MIR21
5	xenobiotic metabolic process	GO:0006805	9.75	GSTP1 HSP90AB1 NAT2
6	positive regulation of peptidyl-serine phosphorylation	GO:0033138	9.73	CD44 EGFR HSP90AB1
7	positive regulation of vascular smooth muscle cell proliferation	GO:1904707	9.63	MIR21 MMP2 TERT
8	cellular response to drug	GO:0035690	9.62	EGFR HSP90AB1 NME1 TP53
9	positive regulation of superoxide anion generation	GO:0032930	9.58	EGFR GSTP1
10	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.55	EGFR TP53
11	mitotic G1 DNA damage checkpoint	GO:0031571	9.54	CCND1 TP53
12	positive regulation of vascular smooth muscle cell differentiation	GO:1905065	9.52	ENG MIR21
13	xenobiotic catabolic process	GO:0042178	9.51	GSTM1 GSTM3
14	nitrobenzene metabolic process	GO:0018916	9.43	GSTM1 GSTM3
15	cellular detoxification of nitrogen compound	GO:0070458	9.4	GSTM1 GSTM3
16	response to UV-A	GO:0070141	9.37	CCND1 EGFR
17	replicative senescence	GO:0090399	9.33	CDKN2A TERT TP53
18	glutathione metabolic process	GO:0006749	9.26	GSTM1 GSTM3 GSTP1 GSTT1
19	glutathione derivative biosynthetic process	GO:1901687	8.92	GSTM1 GSTM3 GSTP1 GSTT1

Molecular functions related to Larynx Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.86	EGFR ENG FHIT GSTM3 HSP90AB1 NME1
2	protein kinase binding	GO:0019901	9.8	CCND1 CDKN2A EGFR GSTP1 HSP90AB1 TP53
3	ubiquitin protein ligase binding	GO:0031625	9.73	EGFR FHIT HSP90AB1 TP53
4	enzyme binding	GO:0019899	9.63	CCND1 EGFR GSTM1 GSTM3 NME1 TP53
5	disordered domain specific binding	GO:0097718	9.54	CDKN2A HSP90AB1 TP53
6	nitric-oxide synthase regulator activity	GO:0030235	9.4	EGFR HSP90AB1
7	glutathione binding	GO:0043295	9.13	GSTM1 GSTM3 GSTP1
8	glutathione transferase activity	GO:0004364	8.92	GSTM1 GSTM3 GSTP1 GSTT1

Sources

Sources for Larynx Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia